BHCM
NGNE icon

Brevan Howard Capital Management’s Neurogene NGNE Stock Holding History

Brevan Howard Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$264K Sell
8,387
-4,367
-34% -$120K ﹤0.01% 1775
2026
Q1 		$257K Buy
+12,754
New +$247K ﹤0.01% 1729
2025
Q4 		– Sell
-12,878
Closed -$223K – 2130
2025
Q3 		$223K Buy
+12,878
New +$259K ﹤0.01% 1703
2024
Q2 		– Sell
-8,064
Closed -$410K – 1288
2024
Q1 		$410K Buy
+8,064
New +$269K ﹤0.01% 524

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Brevan Howard Capital Management's NGNE Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its Neurogene (NGNE) stake by 34% in Q2 2026, selling an estimated $120K and leaving 8,387 shares worth $264K. The position accounts for ﹤0.01% of the portfolio, ranked #1775.

Brevan Howard Capital Management first reported a position in NGNE in Q1 2024 and has held it in 4 quarters since. The position peaked at $410K in Q1 2024. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Brevan Howard Capital Management held 8,387 shares of Neurogene worth $264K as of Q2 2026.
  • Brevan Howard Capital Management sold 4,367 Neurogene shares in Q2 2026, an estimated $120K.
  • Neurogene made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1775 holding.
  • Brevan Howard Capital Management first reported a position in Neurogene in Q1 2024 and has held it in 4 quarters since.
  • Brevan Howard Capital Management's Neurogene position peaked at $410K in Q1 2024.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.